Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIAID AIDS Vaccine Selection Committee

Executive Summary

NIAID establishes 12-member committee to help in decisions on which potential AIDS vaccines now being tested in laboratories are "promising enough" to be tested in humans. In addition, committee will recommend minimum guidelines manufacturers must meet for eligibility for Phase I trials and for being considered for Phase II studies. Committee members include PMA VP-Medical and Regulatory Affairs John Petricciani and FDA Biological IND Division Deputy Director Janet Woodcock.

You may also be interested in...



Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold

The US FDA appears to have concerns about the device used to administer the vaccine.

US Lab-Testing Certification Process Will Be Streamlined Under Quick-Start Guide, CMS Says

The US Medicare agency has released a quick-start guide for laboratory certification.

Washington State Ecology Mulls ‘Safer’ Definition While Exploring Phthalate Alternatives In Fragrances

Marissa Smith, senior regulatory toxicologist in the Washington Department of Ecology’s Hazardous Waste and Toxics Reduction program, discusses what’s next for the state’s inaugural Safer Products go-round. “How we define ‘safer’ is really going to be the lynchpin of this whole process,” she says.

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel